ArticleEuropean journal of radiology open2025
Potential of spectral imaging generated by contrast-enhanced dual-energy CT for lung cancer histopathological classification - A preliminary study.
Article in European journal of radiology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spectral CT Electron Density Mapping for Lung Biopsy Targeting.Radiology. Imaging cancer · 2026Article
- Dual-layer spectral detector CT electron density imaging: impressive technology for imaging characteristics of ground-glass nodules.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The potential of spectral images, particularly electron density and effective Z-images, generated by dual-energy computed tomography (DECT), for the histopathologic classification of lung cancer remains unclear. This study aimed to explore which imaging factors could better reflect the histopathological status of lung cancer. Method: The data of 31 patients who underwent rapid kV-switching DECT and subsequently underwent surgery for lung cancer were analyzed. Virtual monochromatic images (VMIs) of 35 keV and 70 keV, virtual non-contrast images (VNC), iodine content images, electron density images, and effective Z-images were reconstructed for the following analyses: 1) correlation with the ratio of the lepidic growth pattern in the whole tumor and 2) comparisons with the four histological groups: well-differentiated adenocarcinoma (WDA), moderately differentiated adenocarcinoma (MDA), and poorly differentiated adenocarcinoma (PDA) and squamous cell carcinoma (SCC). Results: There were significant correlations between the ratio of lepidic growth pattern and 70 keV, 35 keV, VNC, and electron density images (r = -0.861, P < 0.001; r = -0.791, P < 0.001; r = -0.869, P < 0.001; r = -0.871, P < 0.001, respectively). There were significant differences in the 70 keV, 35 keV, VNC, and electron density images in the Kruskal-Wallis test (P = 0.001, P = 0.006, P < 0.001, P < 0.001, respectively). However, there were no significant differences in iodine content or effective Z-images. Conclusions: Electron density images generated by spectral imaging may be better indicators of the histopathological classification of lung cancer. Clinical relevance: Electron density images may have an added value in predicting the histopathological classification of lung cancer. Key points: •The role of electron density and effective Z-images obtained using dual-energy CT in lung cancer classification remains unclear.•Electron density and virtual non-contrast images correlated better with the ratio of lepidic growth patterns in lung cancer.•Electron density imaging is a better indicator of the histopathological classification of lung cancer than effective Z-imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.